Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E20.48 EPS (ttm)20.70 Insider Own0.90% Shs Outstand106.22M Perf Week4.21%
Market Cap45.03B Forward P/E17.26 EPS next Y24.57 Insider Trans-1.22% Shs Float76.03M Perf Month4.80%
Income2.38B PEG1.91 EPS next Q5.57 Inst Own72.90% Short Float2.39% Perf Quarter23.93%
Sales6.71B P/S6.71 EPS this Y57.40% Inst Trans-0.95% Short Ratio2.42 Perf Half Y17.16%
Book/sh81.00 P/B5.23 EPS next Y7.54% ROA23.40% Target Price417.27 Perf Year28.21%
Cash/sh26.45 P/C16.03 EPS next 5Y10.73% ROE32.20% 52W Range281.89 - 431.32 Perf YTD13.51%
Dividend- P/FCF24.85 EPS past 5Y40.30% ROI24.90% 52W High-1.70% Beta1.21
Dividend %- Quick Ratio3.90 Sales past 5Y26.10% Gross Margin93.50% 52W Low50.40% ATR10.27
Employees7400 Current Ratio4.50 Sales Q/Q21.80% Oper. Margin37.80% RSI (14)60.26 Volatility2.29% 2.62%
OptionableYes Debt/Eq0.00 EPS Q/Q54.50% Profit Margin36.40% Rel Volume0.93 Prev Close414.97
ShortableYes LT Debt/Eq0.08 EarningsFeb 06 BMO Payout0.00% Avg Volume748.36K Price423.97
Recom2.50 SMA202.20% SMA507.76% SMA20016.21% Volume699,622 Change2.17%
Jan-04-19Upgrade Guggenheim Neutral → Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Feb-15-19 04:41PM  U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor PR Newswire
Feb-14-19 09:30AM  Regeneron Announces Upcoming Investor Conference Presentation PR Newswire
Feb-13-19 03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
Feb-12-19 09:30AM  Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year? Zacks
08:56AM  Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60% Zacks
08:30AM  New Research Coverage Highlights Overstock, Regeneron Pharmaceuticals, Molecular Templates, The Ensign Group, Limoneira, and Primo Water Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-11-19 12:39PM  Regeneron will spend up to $490 million on manufacturing, labs this year American City Business Journals
11:45AM  Regenerons 60% Price Cut Shows Heat Is Still on Drug Companies
07:18AM  Sanofi and Regeneron cut list price of cholesterol drug by 60 percent Reuters
07:00AM  Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price PR Newswire
07:00AM  Sanofi and Regeneron cut list price of cholesterol drug by 60 pct Reuters
06:59AM  Regeneron and Sanofi Offer Praluent® (alirocumab) at a New Reduced U.S. List Price PR Newswire
12:24AM  [$$] Sanofi and Regeneron cut price of Praluent by 60% Financial Times
Feb-09-19 04:30PM  One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium PR Newswire
Feb-08-19 10:25AM  The Zacks Analyst Blog Highlights: Chevron, CSX, Regeneron, Capital One and Canadian National Zacks
09:45AM  Edited Transcript of REGN earnings conference call or presentation 6-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
07:06AM  What Can We Expect From Regeneron Pharmaceuticals, Inc.s (NASDAQ:REGN) Earnings In The Year Ahead? Simply Wall St.
Feb-07-19 08:48PM  Regeneron Pharmaceuticals Inc (REGN) Files 10-K for the Fiscal Year Ended on December 31, 2018
03:41PM  Top Stock Reports for Chevron, CSX Corporation & Regeneron Zacks
08:32AM  Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth Zacks
06:00AM  Regeneron profits double ahead of $800 million expansion American City Business Journals
Feb-06-19 05:32PM  Regeneron Pharmaceuticals Inc (REGN) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:46PM  Snap and Capri Holdings rise while Electronic Arts tumbles Associated Press
04:13PM  Why Regeneron's Key Drug 'Did Not Disappoint' In The Fourth Quarter Investor's Business Daily
01:52PM  Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea Zacks
10:12AM  Stocks Turn Lower, But These Top Stocks Break Out On Earnings Investor's Business Daily
07:50AM  Regeneron (REGN) Q4 Earnings and Revenues Surpass Estimates Zacks
07:06AM  Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink Zacks
06:57AM  Regeneron: 4Q Earnings Snapshot Associated Press
06:30AM  Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results PR Newswire
01:34AM  Regeneron Pharma Earnings, Revenue beat in Q4
Feb-05-19 04:06PM  Match Leads 8 Stocks Eyeing Buy Points With Earnings Due: Action Plan Investor's Business Daily
03:02PM  3 Biotech Stocks That Pay Solid Dividends InvestorPlace
02:15PM  Regeneron Pharmaceuticals Q4 Earnings Preview Benzinga
09:53AM  Sanofi's Myeloma Candidate Meets Goal in Phase III Study Zacks
Feb-04-19 08:58AM  Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store? Zacks
06:33AM  Evolus Rises Midday as Botox Drama Unfolds
01:02AM  Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease GlobeNewswire
12:59AM  CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease PR Newswire
Feb-02-19 02:17PM  Pricing Pressure a Hard Pill for Pharma to Swallow
Jan-31-19 07:26PM  Alexion (ALXN) to Report Q4 Earnings: What's in the Cards? Zacks
08:51AM  4 Healthcare Stocks Likely to Beat Estimates in Q4 Zacks
Jan-30-19 08:52AM  Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study Zacks
Jan-29-19 09:30PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jan-28-19 04:17AM  Amgen (AMGN) to Report Q4 Earnings: What's in the Cards? Zacks
Jan-24-19 10:51AM  The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio Zacks
Jan-23-19 12:01PM  Forty of the Nation's Most Brilliant Young Scientists Named Finalists in Regeneron Science Talent Search 2019 PR Newswire
10:48AM  5 Best Biotech Bets Likely to Outperform Estimates in Q4 Zacks
09:31AM  Is a Beat in Store for AbbVie (ABBV) This Earnings Season? Zacks
Jan-20-19 10:15AM  3 Healthcare Stocks Hitting 52-Week Highs: Are They Buys? Motley Fool
Jan-18-19 04:12PM  These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts Investor's Business Daily
04:01PM  Regeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2019 PR Newswire
09:10AM  Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies Zacks
Jan-17-19 03:04PM  Stock Market Jumps On China Tariff News; Netflix Holds Tight Ahead Of Results Investor's Business Daily
09:06AM  J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect Zacks
07:40AM  Report: Exploring Fundamental Drivers Behind SkyWest, Pacific Biosciences of California, Lennar, Regeneron Pharmaceuticals, MGM Growth Properties, and Cincinnati Bell New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-16-19 04:55PM  Regeneron (REGN) Sails Steady on Label Expansion of Drugs Zacks
12:08PM  REIT Stocks, Medical Stocks Lead New Buys By The Best Mutual Funds Investor's Business Daily
Jan-15-19 03:04PM  3 of the Top Big Pharma Stocks to Buy Now InvestorPlace
02:26PM  Can Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Maintain Its Strong Returns? Simply Wall St.
11:15AM  How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support Investor's Business Daily
10:19AM  5 Companies Hit 52-Week Highs
10:10AM  Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive? Zacks
Jan-11-19 09:04AM  3 Biotech Stocks Bubbling Away Investopedia
Jan-10-19 12:57PM  Oakmark Funds Bill Nygren Discusses Poor Q4 Performance He Is Not Losing Confidence Insider Monkey
Jan-09-19 01:46PM  Market Leaderships Odd Couple: Wingstop and Regeneron InvestorPlace
09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-08-19 08:56AM  4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks
Jan-07-19 06:18PM  Regeneron, Sanofi Restructure Immuno-Oncology Collaboration Zacks
02:28PM  U.S. top court rejects Amgen over cholesterol medication patent fight Reuters
02:25PM  U.S. top court rejects Amgen over cholesterol medication patent fight Reuters
12:33PM  Sanofi to pay Regeneron $462 million in revised immuno-oncology deal Reuters
12:21PM  UPDATE 1-Sanofi to pay Regeneron $462 mln in revised immuno-oncology deal Reuters
07:00AM  Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference PR Newswire
02:51AM  Drugmakers Sanofi, Regeneron restructure immuno-oncology deal Reuters
02:32AM  Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs GlobeNewswire
02:30AM  Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs PR Newswire
Jan-04-19 11:30AM  Regeneron Stock Is the Latest Biotech Bottle Rocket +6.85%
11:08AM  The 3 Best Stocks to Buy At the End of the Bear Market InvestorPlace
Dec-31-18 04:15PM  Does Pfizer Have A Multibillion-Dollar Replacement For Opioids? Investor's Business Daily
Dec-26-18 03:12PM  Value Investors Should Buy into the Teva Stock Dip InvestorPlace +6.65%
Dec-24-18 10:08AM  Health care going negative after starting quarter strong CNBC Videos
Dec-20-18 01:23PM  Regeneron to receive up to $140 million from state toward $800 million expansion American City Business Journals
Dec-19-18 08:03AM  How Should Investors Feel About Regeneron Pharmaceuticals, Inc.s (NASDAQ:REGN) CEO Pay? Simply Wall St.
Dec-18-18 04:01PM  Regeneron Announces Presentation at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-17-18 09:08AM  5 Excellent GARP Picks With Cheap PEG Ratio Zacks
Dec-14-18 10:50AM  Global fears strike Wall Street Yahoo Finance
Dec-13-18 06:00AM  Chris Childrose has hired 1,500 employees. Shes only halfway done American City Business Journals
Dec-12-18 03:17AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen Zacks
Dec-11-18 10:26AM  Moderna Stock Ushers In the Next Wave of Biotech InvestorPlace
09:00AM  4 Biotech Stocks Investors Can Add to Their Portfolio in 2019 Zacks
12:59AM  Hedge Funds Are Crazy About Regeneron Pharmaceuticals Inc (REGN) Insider Monkey
Dec-06-18 01:48PM  3 Top Stocks After #ASH18 Motley Fool
Dec-04-18 03:13PM  Eye Drug Continues to Drive Regeneron's Growth
07:00AM  Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE
Dec-03-18 08:00AM  Detailed Research: Economic Perspectives on TESARO, Regeneron Pharmaceuticals, Pool, Zebra Technologies, Cadence Design, and TherapeuticsMD What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-01-18 12:00PM  Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma PR Newswire
12:00PM  Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals Motley Fool
Nov-28-18 05:19PM  Galapagos' Osteoarthritis Candidate Gets Fast Track Status Zacks
Nov-23-18 06:46AM  Why I Like Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Simply Wall St.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fenimore Christopher R.VP ControllerJan 18Option Exercise21.251503,1887,246Jan 18 05:01 PM
GOLDSTEIN JOSEPH LDirectorJan 10Option Exercise273.671,791490,14314,114Jan 11 04:06 PM
GOLDSTEIN JOSEPH LDirectorJan 10Sale410.001,791734,31012,323Jan 11 04:06 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise21.2567514,3448,944Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 20Sale358.971,848663,3817,096Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 19Option Exercise52.033,450179,5049,871Dec 20 05:36 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 13Option Exercise16.80244,0484,100,006167,185Dec 17 04:02 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise16.80312,5005,250,000488,014Dec 14 04:19 PM
VAGELOS P ROYChairman of the BoardDec 12Sale382.3262,2942,304Dec 14 04:49 PM
GOLDSTEIN JOSEPH LDirectorSep 28Option Exercise273.67709194,03212,709Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 28Sale410.00709290,69012,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 27Option Exercise273.672,000547,34014,000Oct 01 04:06 PM
BROWN MICHAEL SDirectorSep 27Option Exercise273.672,000547,3402,000Sep 28 04:35 PM
BROWN MICHAEL SDirectorSep 27Sale392.262,000784,5240Sep 28 04:35 PM
GOLDSTEIN JOSEPH LDirectorSep 27Sale400.002,000800,00012,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 24Option Exercise273.672,000547,34013,000Sep 25 04:05 PM
GOLDSTEIN JOSEPH LDirectorSep 24Sale388.652,000777,29012,000Sep 25 04:05 PM
Fenimore Christopher R.VP ControllerAug 30Option Exercise21.25501,063200Aug 31 04:02 PM
BROWN MICHAEL SDirectorAug 22Option Exercise177.821,500266,7301,500Aug 23 04:01 PM
BROWN MICHAEL SDirectorAug 22Sale380.491,500570,7350Aug 23 04:01 PM
VAGELOS P ROYChairman of the BoardAug 20Option Exercise21.252104,463400,057Aug 21 04:55 PM
GOLDSTEIN JOSEPH LDirectorAug 02Option Exercise57.112,000114,22014,000Aug 03 04:03 PM
GOLDSTEIN JOSEPH LDirectorAug 02Sale380.002,000760,00012,000Aug 03 04:03 PM
VAGELOS P ROYChairman of the BoardJul 10Sale367.2274,67027,420,277399,847Jul 11 04:04 PM
VAGELOS P ROYChairman of the BoardJul 09Option Exercise16.80153,2742,575,003553,121Jul 11 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Sale370.002,000740,00012,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Sale360.002,000720,00012,000Jul 09 04:04 PM
VAGELOS P ROYChairman of the BoardJun 21Sale327.8774,71024,495,410399,847Jun 22 04:03 PM
VAGELOS P ROYChairman of the BoardJun 20Option Exercise16.80153,2742,575,003553,121Jun 22 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 24Sale295.0911,4073,366,09231,973May 25 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 23Option Exercise30.6326,736818,92458,709May 25 04:03 PM
SING GEORGE LDirectorMay 10Sale286.6213,0003,726,000114,772May 11 04:02 PM
SING GEORGE LDirectorMay 09Sale285.297,0001,997,030127,772May 11 04:02 PM
GOLDSTEIN JOSEPH LDirectorMar 19Option Exercise57.112,000114,22014,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 19Sale350.022,000700,04012,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 14Option Exercise57.112,000114,22014,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorMar 14Sale340.002,000680,00012,000Mar 14 04:01 PM